AFT Pharmaceuticals (AFT Pharmaceuticals) YoY EBITDA Growth : 27.62% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is AFT Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. AFT Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 27.62%.

AFT Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was $0.13.

AFT Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for AFT Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AFT Pharmaceuticals YoY EBITDA Growth Chart

AFT Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

YoY EBITDA Growth

Get a 7-Day Free Trial

200.00

-36.30

68.60

-16.55

33.06

AFT Pharmaceuticals Quarterly Data
	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial												123.40	21.05	49.23	-38.10	27.62

AFT Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

AFT Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (A: Mar. 2024 )
=	(EBITDA per Share (A: Mar. 2024 )	-	EBITDA per Share (A: Mar. 2023 ))	/	\| EBITDA per Share (A: Mar. 2023 ) \|
=	(0.161	-	0.121)	/	\| 0.121 \|
=	33.06 %

AFT Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2022 ))	/	\| EBITDA per Share (Q: Mar. 2022 )) \|
=	(0.134	-	0.105)	/	\| 0.105 \|
=	27.62 %

AFT Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of AFT Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

AFT Pharmaceuticals (AFT Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (OTCPK:AFTPF) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

AFT:New Zealand AFP:Australia

Address

129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622

Website

https://www.aftpharm.com

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.